In a study by Bliesath et al., EGFR and CK2 were inhibited with a combination of CX-4945 and erlotinib (i.e., EGFR tyrosine kinase inhibitor) in in vitro models of cancer (non-small cell lung carcinoma, squamous cell carcinoma cells). This evidence concerns the gene EGFR and non-small cell lung carcinoma.